Innovative antifibrotic therapies in systemic sclerosis

Current Opinion in Rheumatology

Volumn 24, Issue 3, 2012, Pages 274-280

  Beyer, Christian ^a   Distler, Oliver ^b   Distler, Jörg H W ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

fibrosis; systemic sclerosis; targeted therapies

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIFIBROTIC AGENT; DASATINIB; DNA METHYLTRANSFERASE; GAMMA SECRETASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INTERLEUKIN 6; METELIMUMAB; NILOTINIB; NOTCH RECEPTOR; RITUXIMAB; SMAD3 PROTEIN; SMAD4 PROTEIN; TERGURIDE; TOCILIZUMAB; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A;

APOPTOSIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG TOLERABILITY; FIBROBLAST; HUMAN; LUNG FIBROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE;

EPIGENESIS, GENETIC; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; MORPHOGENESIS; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84859247939     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283524b9a     Document Type: Review

References (49)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009; 360:1989-2003
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117:557-567 (Pubitemid 46348510)
3. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-1815
4. Distler JH, Distler O. Criteria to select molecular targets for antifibrotic therapy. Rheumatology (Oxford) 2008; 47 (Suppl 5):v12-v13
5. Riemekasten G, Philippe A, Nather M, et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70:530-536
6. Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12:R54
7. Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60:578-583
8. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010; 49:271-280
9. Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010; 69:193-197
10. Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research Group. Arthritis Rheum 2011;Suppl. 63, 702
11. Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010; 49:2408-2412
12. Meunier M, Matucci-Cerinic M, Maurer B, et al. Outcomes Of systemic sclerosis associated polyarthritis patients treated by biotherapies tocilizumab or abatacept: a EUSTAR Observational Study. Ann Rheum Dis 2011; 70 (Suppl 3):660
13. Rankin AL, Mumm JB, Murphy E, et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010; 184:1526-1535
14. Aliprantis AO, Wang J, Fathman JW, et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA 2007; 104:2827-2830 (Pubitemid 46327964)
15. Medsger TA Jr, Ivanco DE, Kardava L, et al. GATA-3 up-regulation in CD8 + T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production. Arthritis Rheum 2011; 63:1738-1747
16. Denton CP, Merkel PA, Furst DE, et al. Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56:323-333 (Pubitemid 46106206)
17. Akhmetshina A, Venalis P, Dees C, et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 2009; 60:219-224
18. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56:311-322 (Pubitemid 46106205)
19. Beyer C, Distler JH, Distler O. Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? Swiss Med Wkly 2010; 140:w13050
20. Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010; 181:604-610
21. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graftversus-host disease with fibrotic features. Blood 2009; 114:709-718
22. Magro L, Catteau B, Coiteux V, et al. Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD. Bone Marrow Transplant 2008; 42:757-760
23. Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70:1003-1009
24. Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse systemic sclerosis: a single site trial. Arthritis Rheum 2011; 63:3547-3551
25. Khanna D, Saggar R, Mayes MD, et al. Open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis-associated active interstitial lung disease (SSc-ILD). Arthritis Rheum 2011; 63:3540-3546
26. Distler O, Distler JH, Varga J, et al. A Multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis. Arthritis Rheum 2010; 62 (Suppl 10):560
27. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354:2655-2666
28. Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond: exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009; 6:535-543
29. Akhmetshina A, Dees C, Pileckyte M, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J 2008; 22:2214-2222 (Pubitemid 351948641)
30. Aoki Y, Maeno T, Aoyagi K, et al. Pioglitazone, a peroxisome proliferatoractivated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009; 77:311-319
31. Burgess HA, Daugherty LE, Thatcher TH, et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005; 288:L1146-L1153 (Pubitemid 40695441)
32. Milam JE, Keshamouni VG, Phan SH, et al. PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008; 294:L891-L901
33. Dees C, Akhmetshina A, Zerr P, et al. Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med 2011;208:961-972.
34. Huber LC, Distler JH, Moritz F, et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum 2007; 56:2755-2764 (Pubitemid 47237295)
35. Hemmatazad H, Rodrigues HM, Maurer B, et al. Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. Arthritis Rheum 2009; 60:1519-1529
36. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54:2271-2279 (Pubitemid 44051084)
37. Dees C, Akhmetshina A, Busch N, et al. Inhibitors of DNA methyltransferases expert potent antifibrotic effects via reactivation of SOCS-3. Copenhagen: EULAR; 2009
38. Bechtel W, McGoohan S, Zeisberg EM, et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 2010; 16:544-550.
39. Andersson ER, Sandberg R, Lendahl U. Notch signaling: simplicity in design, versatility in function. Development 2011; 138:3593-3612
40. Barakat MT, Humke EW, Scott MP. Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. Trends Mol Med 2010; 16:337-348
41. Grigoryan T, Wend P, Klaus A, et al. Deciphering the function of canonical Wnt signals in development and disease: conditional loss-and gain-offunction mutations of beta-catenin in mice. Genes Dev 2008; 22:2308-2341
42. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma? Arthritis Rheum 2011; 63:1707-1717.
43. Akhmetshina A, Palumbo K, Bergmann C, et al. Interaction of canonical Wnt signaling and transforming growth factor-b is crucial for the development of fibrosis. Nat Communications (in press).
44. Beyer C, Schramm A, Akhmetshina A, et al. b-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis [Epub ahead of print]
45. Bergmann C, Akhmetshina A, Dees C, et al. Inhibition of glycogen synthase kinase 3beta induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis 2011; 70:2191-2198
46. Horn A, Palumbo K, Cordazzo C, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum 2012. doi: 10.1002/art.34444.[Epub ahead of print]
47. Kavian N, Servettaz A, Mongaret C, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum 2010; 62:3477-3487.
48. Dees C, Tomcik M, Zerr P, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011; 70:1304-1310
49. Dees C, Zerr P, Tomcik M, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011; 63:1396-1404.